Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Maria Soledad Ormaechea, Muhammad Hassan, Neil Onghanseng, Jung Hyun Park, Sarakshi Mahajan, Khalid Yusuf Al-Kirwi, Gunay Uludag, Muhammad Sohail Halim, Ariel Schlaen, Yasir J Sepah, Diana V Do & Quan Dong Nguyen. (2019) Safety of systemic therapy for noninfectious uveitis. Expert Opinion on Drug Safety 18:12, pages 1219-1235.
Read now
Read now
Emilio Besada. (2014) Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. Patient Preference and Adherence 8, pages 1051-1059.
Read now
Read now
Matteo Nicola Dario Di Minno, Pasquale Ambrosino, Rosario Peluso, Alessandro Di Minno, Roberta Lupoli & Francesco Dentali. (2014) Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: A meta-analysis of prospective studies. Annals of Medicine 46:2, pages 73-83.
Read now
Read now
Articles from other publishers (16)
Eun Hye Park, Eun Young Lee, Kichul Shin & Hyoun-Ah Kim. (2019) Tocilizumab-induced anaphylaxis in patients with adult-onset Still’s disease and systemic juvenile idiopathic arthritis: a case-based review. Rheumatology International 40:5, pages 791-798.
Crossref
Crossref
H Ebe, I Matsumoto, H Kawaguchi, I Kurata, Y Tanaka, A Inoue, Y Kondo, H Tsuboi & T Sumida. (2018) Clinical and functional significance of STEAP4-splice variant in CD14+ monocytes in patients with rheumatoid arthritis. Clinical and Experimental Immunology 191:3, pages 338-348.
Crossref
Crossref
A A Arguinano, E Naderi, N C Ndiaye, M Stathopoulou, S Dadé, B Alizadeh & S Visvikis-Siest. (2017) IL6R haplotype rs4845625*T/rs4537545*C is a risk factor for simultaneously high CRP, LDL and ApoB levels. Genes & Immunity 18:3, pages 163-169.
Crossref
Crossref
T. Flaig, A. Douros, E. Bronder, A. Klimpel, R. Kreutz & E. Garbe. (2016) Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System. Journal of Clinical Pharmacy and Therapeutics 41:6, pages 718-721.
Crossref
Crossref
Tadashi Okano, Kentaro Inui, Masahiro Tada, Yuko Sugioka, Kenji Mamoto, Shigeyuki Wakitani, Tatsuya Koike & Hiroaki Nakamura. (2015) Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. Rheumatology International 36:3, pages 349-357.
Crossref
Crossref
Edyta Brzustewicz & Ewa Bryl. (2015) The role of cytokines in the pathogenesis of rheumatoid arthritis – Practical and potential application of cytokines as biomarkers and targets of personalized therapy. Cytokine 76:2, pages 527-536.
Crossref
Crossref
Daniela Rossi, Vittorio Modena, Savino Sciascia & Dario Roccatello. (2015) Rheumatoid arthritis: Biological therapy other than anti-TNF. International Immunopharmacology 27:2, pages 185-188.
Crossref
Crossref
Sara J. Ireland, Nancy L. Monson & Laurie S. Davis. (2015) Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10. Cytokine 73:2, pages 236-244.
Crossref
Crossref
C Takai, I Matsumoto, A Inoue, N Umeda, Y Tanaka, Y Kurashima, Y Wada, I Narita & T Sumida. (2015) Specific overexpression of tumour necrosis factor-α-induced protein (TNFAIP)9 in CD14+CD16− monocytes in patients with rheumatoid arthritis: comparative analysis with TNFAIP3. Clinical and Experimental Immunology 180:3, pages 458-466.
Crossref
Crossref
Go Woon Kim, Na Ra Lee, Ryo Han Pi, Yee Seul Lim, Yu Mi Lee, Jong Min Lee, Hye Seung Jeong & Sung Hyun Chung. (2015) IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. Archives of Pharmacal Research 38:5, pages 575-584.
Crossref
Crossref
Violeta Régnier Galvão & Mariana C. Castells. (2015) Hypersensitivity to Biological Agents—Updated Diagnosis, Management, and Treatment. The Journal of Allergy and Clinical Immunology: In Practice 3:2, pages 175-185.
Crossref
Crossref
Ian C. Scott, James B. Galloway & David L. ScottIan C. Scott, James B. Galloway & David L. Scott. 2015. Inflammatory Arthritis in Clinical Practice. Inflammatory Arthritis in Clinical Practice
137
153
.
Ae Ri Yoo & Sung Kun Chung. (2014) Effects of Subconjunctival Tocilizumab Versus Bevacizumab in Treatment of Corneal Neovascularization in Rabbits. Cornea 33:10, pages 1088-1094.
Crossref
Crossref
M Mesquida, A Leszczynska, V Llorenç & A Adán. (2014) Interleukin-6 blockade in ocular inflammatory diseases. Clinical and Experimental Immunology 176:3, pages 301-309.
Crossref
Crossref
Carolyn Bornstein, Marie Craig & Diane Tin. (2014) Practice guidelines for pharmacists. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 147:2, pages 97-109.
Crossref
Crossref
Yuxi Li, Peng Wang, Zhongyu Xie, Lin Huang, Rui Yang, Liangbin Gao, Yong Tang, Xin Zhang, Jichao Ye, Keng Chen, Zhaopeng Cai, Yanfeng Wu & Huiyong Shen. (2014) Whole Genome Expression Profiling and Signal Pathway Screening of MSCs in Ankylosing Spondylitis. Stem Cells International 2014, pages 1-11.
Crossref
Crossref